BRPI0509140A - processos para o tratamento de infecção por hiv - Google Patents

processos para o tratamento de infecção por hiv

Info

Publication number
BRPI0509140A
BRPI0509140A BRPI0509140-3A BRPI0509140A BRPI0509140A BR PI0509140 A BRPI0509140 A BR PI0509140A BR PI0509140 A BRPI0509140 A BR PI0509140A BR PI0509140 A BRPI0509140 A BR PI0509140A
Authority
BR
Brazil
Prior art keywords
hiv infection
processes
treating hiv
treating
aids
Prior art date
Application number
BRPI0509140-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Pin-Fang Lin
Beata Nowicka-Sans
Gregory Yamanaka
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0509140(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0509140A publication Critical patent/BRPI0509140A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0509140-3A 2004-03-24 2005-03-01 processos para o tratamento de infecção por hiv BRPI0509140A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
PCT/US2005/006277 WO2005102392A2 (en) 2004-03-24 2005-03-01 Combinations for treating hiv infection

Publications (1)

Publication Number Publication Date
BRPI0509140A true BRPI0509140A (pt) 2007-09-04

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509140-3A BRPI0509140A (pt) 2004-03-24 2005-03-01 processos para o tratamento de infecção por hiv

Country Status (30)

Country Link
US (1) US7776863B2 (cg-RX-API-DMAC7.html)
EP (1) EP1732604B1 (cg-RX-API-DMAC7.html)
JP (1) JP4847441B2 (cg-RX-API-DMAC7.html)
KR (1) KR101158140B1 (cg-RX-API-DMAC7.html)
CN (1) CN1956720B (cg-RX-API-DMAC7.html)
AR (1) AR048333A1 (cg-RX-API-DMAC7.html)
AT (1) ATE474602T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005235116B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0509140A (cg-RX-API-DMAC7.html)
CA (1) CA2561146C (cg-RX-API-DMAC7.html)
CY (1) CY1111613T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005022420D1 (cg-RX-API-DMAC7.html)
DK (1) DK1732604T3 (cg-RX-API-DMAC7.html)
ES (1) ES2347801T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20104925B (cg-RX-API-DMAC7.html)
HR (1) HRP20100434T1 (cg-RX-API-DMAC7.html)
IL (1) IL178141A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN06436A (cg-RX-API-DMAC7.html)
MY (1) MY144318A (cg-RX-API-DMAC7.html)
NO (1) NO337116B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ549778A (cg-RX-API-DMAC7.html)
PE (1) PE20060148A1 (cg-RX-API-DMAC7.html)
PL (1) PL1732604T3 (cg-RX-API-DMAC7.html)
PT (1) PT1732604E (cg-RX-API-DMAC7.html)
RU (1) RU2367439C2 (cg-RX-API-DMAC7.html)
SI (1) SI1732604T1 (cg-RX-API-DMAC7.html)
TW (1) TWI347184B (cg-RX-API-DMAC7.html)
UA (1) UA88463C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005102392A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200607959B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US8318931B2 (en) 2005-10-28 2012-11-27 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
EP1961744B1 (en) 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
ES2462403T3 (es) 2008-06-25 2014-05-22 Bristol-Myers Squibb Company Diceto azolopiperidinas y azolopiperazinas como agentes anti-VIH
US8242124B2 (en) * 2008-06-25 2012-08-14 Bristol-Myers Squibb Company Diketopiperidine derivatives as HIV attachment inhibitors
US20110290821A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
EP2601174B1 (en) 2010-08-06 2014-11-26 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
WO2012075235A1 (en) 2010-12-02 2012-06-07 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
RS54055B1 (sr) 2011-01-31 2015-10-30 Bristol-Myers Squibb Company POSTUPCI ZA PRIPREMU JEDINJENJA PROLEKA INHIBITORA VEZIVANJA HIV-a I INTERMEDIJERA
WO2012142080A1 (en) 2011-04-12 2012-10-18 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
ES2616268T3 (es) 2011-08-29 2017-06-12 VIIV Healthcare UK (No.5) Limited Derivados condensados de diamina bicíclica como inhibidores de la unión de VIH
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
US9193725B2 (en) 2012-03-14 2015-11-24 Bristol-Meyers Squibb Company Cyclic hydrazine derivatives as HIV attachment inhibitors
ES2616492T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de piperidina amida como inhibidores de la fijación del VIH
WO2014025852A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic alkene derivatives as hiv attachment inhibitors
PT2978763T (pt) * 2013-03-27 2018-04-16 Viiv Healthcare Uk No 5 Ltd Derivados de 2-cetoamida como inibidores da ligação do vih
EP3313412A4 (en) 2015-06-23 2019-01-16 CytoDyn Inc. INHIBITION OF CCL5 LIGAND BINDING AT CCR5 RECEPTOR AND CHANGING CCR5 / CCL5 AXIS SIGNALING IN INFUSION, CANCER, AUTOIMMUNE AND OTHER DISORDERS
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348839T1 (de) * 1998-03-02 2007-01-15 Univ North Carolina Acylierte betulin- und dihydrobetulinderivate, ihre herstellung und verwendung
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
WO2003049690A2 (en) * 2001-12-12 2003-06-19 Bristol-Myers Squibb Company Hiv integrase inhibitors
CN102153540A (zh) * 2001-12-21 2011-08-17 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物

Also Published As

Publication number Publication date
JP2007530540A (ja) 2007-11-01
EP1732604A2 (en) 2006-12-20
GEP20104925B (en) 2010-03-25
US20050215545A1 (en) 2005-09-29
NZ549778A (en) 2010-09-30
DE602005022420D1 (de) 2010-09-02
DK1732604T3 (da) 2010-11-15
JP4847441B2 (ja) 2011-12-28
UA88463C2 (ru) 2009-10-26
WO2005102392A3 (en) 2006-07-20
CN1956720B (zh) 2010-12-15
HK1096540A1 (en) 2007-06-01
AU2005235116A1 (en) 2005-11-03
US7776863B2 (en) 2010-08-17
RU2006137555A (ru) 2008-04-27
IL178141A0 (en) 2006-12-31
ES2347801T3 (es) 2010-11-04
NO20064547L (no) 2006-10-06
IL178141A (en) 2010-11-30
PL1732604T3 (pl) 2010-12-31
CY1111613T1 (el) 2015-10-07
MY144318A (en) 2011-08-29
HRP20100434T1 (hr) 2010-09-30
AU2005235116B2 (en) 2011-03-31
CN1956720A (zh) 2007-05-02
RU2367439C2 (ru) 2009-09-20
PT1732604E (pt) 2010-09-24
EP1732604B1 (en) 2010-07-21
SI1732604T1 (sl) 2010-10-29
PE20060148A1 (es) 2006-03-04
CA2561146C (en) 2013-12-24
NO337116B1 (no) 2016-01-25
AR048333A1 (es) 2006-04-19
TW200538117A (en) 2005-12-01
KR20070011322A (ko) 2007-01-24
CA2561146A1 (en) 2005-11-03
ZA200607959B (en) 2008-06-25
WO2005102392A2 (en) 2005-11-03
KR101158140B1 (ko) 2012-06-19
ATE474602T1 (de) 2010-08-15
IN2012DN06436A (cg-RX-API-DMAC7.html) 2015-10-09
TWI347184B (en) 2011-08-21

Similar Documents

Publication Publication Date Title
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
EP2081435A4 (en) HAMMER OF BRUTON TYROSINE KINASE
EP2494059A4 (en) USE OF METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL ACTIVITY
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
BRPI0418384A (pt) composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes
WO2006034001A3 (en) Methods of treating hiv infection
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
ATE458750T1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
ATE532509T1 (de) Mittel zur hemmung des eintritts des hiv-virus
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral
BRPI0413132A (pt) composições e compostos bicìclicos como inibidores de pdf
BRPI0409586A (pt) ácidos hidroxámicos úteis no tratamento de distúrbios hiperproliferativos
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ATE441461T1 (de) Mittel zur behandlung von infektionen
BRPI0402854A (pt) tratamento e estudo do melanoma com a utilização dos compostos 1,3,4-tiadiazois mesoiÈnicos
UA95094C2 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства
MY140242A (en) BICYCLIC 6-ALKYLIDENE-PENEMS AS ß-LACTAMASES INHIBITORS
PT1355650E (pt) Combinacao de ingredientes activos contendo alfuzosina e apomorfina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: VIIV HEALTHCARE UK (NO.4) LIMITED (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL